Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Streamline the choice of therapeutic direction for your projects by qualifying the potential of your molecules and your in vitro targets.
T.O.T. qualifies the therapeutic potential of a target or molecule in vitro: cell imaging, new phenotype tests on 3D tissue cultures, molecular characterization of signaling pathways, etc.
Linked to our patient-derived PDX experimental models and the analysis of associated clinical data, T.O.T. Allows you to experimentally reconstruct a patient cohort in order to confirm or adjust a preclinical and clinical development strategy.